Spine

• Proton beam therapy is a more precise treatment that can better focus radiation on a cancer, reducing the side-effects of treatment.
• This leads to better cognitive function and fewer long-term side-effects among patients who receive proton therapy compared to X-ray (photon) treatment.
• Although proton therapy is more expensive to deliver than photon radiation, studies have shown long-term cost-effectiveness of proton beam therapy for medulloblastoma.
• In a study of more than 1,000 adults with other types of locally advanced cancer, proton therapy led to fewer unplanned hospitalizations.

Canadian patients need to travel for treatment

• Researchers in the U.K. estimate that up to 15 per cent of all patients with curable cancers may benefit from proton therapy.
• However, without a domestic facility, Canadians who need proton beam therapy must travel out-of-country to receive this medically necessary treatment for their cancer.

Patients who are able to travel out-of-country report high levels of stress and feelings of isolation. Many of these concerns would be reduced with a domestic, Canadian proton therapy facility.

Progress toward Canadian facilities

In 2016, Québec announced a partnership with a private health-care company to build a standalone proton therapy facility in Montréal.

• It is recognized that the per-patient cost to deliver proton therapy would be less if a Canadian facility were available.
• Canadian doctors and patients eagerly await the day when a cancer patient can receive this advanced treatment without travelling out of country.
• Having access to proton therapy would also allow Canadian researchers to collaborate globally in scientific studies.

Derek Tsang receives research grant funding from ACCESS (https://accessforkidscancer.ca), the Brain Tumour Foundation of Canada, and the US National Cancer Institute. Tsang also received travel funding from Mevion Medical Systems in 2022.

• The company also proudly announces the promotion of Carter Lonsberry to become the Executive Chairman of the Board, signaling a significant strengthening of its leadership team.
• Christoph Eigenmann joins icotec Medical with an impressive track record in the medical technology industry.
• Carter Lonsberry who led icotec US successfully in the first couple years, is appointed to become the US executive Chairman of the Board.
• Roger Stadler, Group CEO of icotec ag, expressed his enthusiasm: "We are thrilled to welcome Christoph Eigenmann as our new US CEO.

• Leo Chang, co-founder and CEO of BodyKore , a leading commercial-grade fitness equipment company specializing in home gym design, is hoping to help change that.
• Airlifted to Mission Hospital, Chang's journey of recovery began with a daunting prognosis and a determination to return to his normal life for his family and company.
• Chang's emotional resilience and immediate focus on recovery set the tone for his rehabilitation journey.
• In line with these strategies, BodyKore is committed to supporting you in your journey towards better health and wellness.

• IDE approval from the FDA serves as a key milestone for this platform and will generate its first human clinical data, thus opening a new chapter in Theradaptive's growth into a clinical-stage company.
• Theradaptive's path to FDA IDE approval has been aided by their unprecedented three Breakthrough Medical Device Designations which provide them with priority review and interactive communication regarding device development and clinical trial protocols.
• John Greenbaum, SVP of Regulatory & Clinical Affairs at Theradaptive, said: "The FDA created Breakthrough Device Designations to accelerate the clinical trials and approval processes for devices that promise to improve on current treatments for life-threatening and debilitating conditions.
• Based on the safety profile of OsteoAdapt, we will be allowed to combine Phase I and II trials.